1. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.60
Figure 3 Examples of existing and potential anticancer drugs that target metabolic processes
Figure 3 | Examples of existing and potential anticancer drugs that target metabolic processes. Several pathways of the bioenergetic and anabolic metabolism of malignant cells harbour targets for the treatment of cancer. In general, agents that disrupt these pathways would be expected to result in deficiencies in energy and materials needed for cell proliferation and, potentially, survival, forming the basis for their use as anticancer therapies. For example, depletion of arginine or glutamate would be expected to cause metabolic collapse in cancer cells. Inhibiting ROS production, autophagy, or glycolysis in the catabolic compartment might also be an effective anticancer strategy. 2DG, 2-deoxyglucose; BP, bisphosphate (or bisphospho); BPTES, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3; CoA, coenzyme A; DCA, dichloroacetate; GLUT1/GLUT4, glucose transporter 1/4; MCT1, monocarboxylate transporter 1; MCT4, monocarboxylate transporter 4; NAC, N-acetylcysteine; OXPHOS, oxidative phosphorylation; P, phosphate (or phospho); ROS, reactive oxygen species; TCA, tricarboxylic acid.
Martinez-Outschoorn, U. E. et al. (2016) Cancer metabolism: a therapeutic perspective
Nat. Rev. Clin. Oncol. doi: /nrclinonc